[0124] 43. Elnakat H, Ratnam M: Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy, Advanced drug delivery reviews 2004, 56:1067-1084

[0125] 44. Parker N, Turk M J, Westrick E, Lewis J D, Low P S, Leamon C P: Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay, Analytical biochemistry 2005, 338:284-293

[0126] 45. Weitman S D, Lark R H, Coney L R, Fort D W, Frasca V, Zurawski V R, Jr., Kamen B A: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues, Cancer research 1992, 52:3396-3401

[0127] 46. Kane M A, Elwood P C, Portillo R M, Antony A C, Najfeld V, Finley A, Waxman S, Kolhouse J F: Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells, The Journal of clinical investigation 1988, 81:1398-1406

[0128] 47. Cho B K, Roy E J, Patrick T A, Kranz D M: Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells, Bioconjugate chemistry 1997, 8:338-346

[0129] 48. Speyer C L, Gao H, Rancilio N J, Neff T A, Huffnagle G B, Sarma J V, Ward P A: Novel chemokine responsiveness and mobilization of neutrophils during sepsis, The American journal of pathology 2004, 165: 2187-2196

[0130] 49. Ethier S P, Mahacek M L, Gullick W J, Frank T S, Weber B L: Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media, Cancer research 1993, 53:627-635

[0131] 50. Tran T, Shatnawi A, Zheng X, Kelley K M, Ratnam M: Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting, Cancer research 2005, 65:4431-4441

[0132] 51. (king-Konert C, Vogt S, Radsak M, Wagner C, Hansch G M, Andrassy K: Polymorphonuclear neutrophils in Wegener's granulomatosis acquire characteristics of antigen presenting cells, Kidney Int 2001, 60:2247-2262

[0133] 52. van Egmond M, van Vuuren A J, Morton H C, van Spriel A B, Shen L, Hofhuis F M, Saito T, Mayadas T N, Verbeek J S, van de Winkel J G: Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18), Blood 1999, 93:4387-4394

[0134] 53. Weisbart R H, Kacena A, Schuh A, Golde D W: GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism, Nature 1988, 332:647-648

[0135] 54. Morton H C, van Egmond M, van de Winkel J G: Structure and function of human IgA Fc receptors (Fc alpha R), Critical reviews in immunology 1996, 16:423-440

[0136] 55. Monteiro R C, Van De Winkel J G: IgA Fc receptors, Annu Rev Immunol 2003, 21:177-204

[0137] 56. Reljic R: In search of the elusive mouse macrophage Fc-alpha receptor, Immunol Lett 2006, 107:80-81

[0138] 57. Prabaharan M, Grailer J J, Pilla S, Steeber D A, Gong S: Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery, Biomaterials 2009, 30:6065-6075

[0139] 58. Prabaharan M, Grailer J J, Pilla S, Steeber D A, Gong S: Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery, Biomaterials 2009, 30:3009-3019

[0140] 59. Prabaharan M, Grailer J J, Steeber D A, Gong S: Thermosensitive micelles based on folate-conjugated poly(N-vinylcaprolactam)-block-poly(ethylene glycol) for tumor-targeted drug delivery, Macromolecular bioscience 2009, 9:744-753

[0141] 60. Li H, Lu Y, Piao L, Wu J, Yang X, Kondadasula S V, Carson W E, Lee R J: Folate-immunoglobulin G as an anticancer therapeutic antibody, Bioconjugate chemistry 2010, 21:961-968

[0142] 61. Speyer C L, Smith J S, Banda M, DeVries J A, Mekani T, Gorski D H: Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer, Breast cancer research and treatment 2012, 132: 565-573

What is claimed is:

1. A conjugate comprising:

an Fc portion of an IgA antibody, wherein said Fc portion comprises a CH2 domain and a CH3 domain but does not comprise a hinge region; and

folate or a folate analog.

2. The conjugate of claim **1**, further comprising a linker.

3. The conjugate of claim **2**, wherein the linker is a peptide linker.

4. The conjugate of claim **2**, herein the linker is a non-peptide linker.

5. The conjugate of claim **1**, wherein the Fc portion is a variant Fc.

6. The conjugate of claim **1**, wherein the Fc portion is a variant Fc and the conjugate comprises folate.

7. The conjugate of claim **1**, wherein the Fc portion is a variant Fc and the conjugate comprises a folate analog.

8. The conjugate of claim **1**, wherein the Fc fragment consists of a CH2/CH3 region from an IgA antibody.

9. The conjugate of claim **1**, formulated for intravenous administration.

10. A method of triggering neutrophil (PMN)-mediated apoptosis of folate receptor alpha (FRA)-expressing cancer cells in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of the conjugate of claim **1**, thereby triggering neutrophil (PMN)-mediated apoptosis of folate receptor alpha (FRA)-expressing cancer cells in the subject.

11. The method of claim **10**, wherein the cancer is breast cancer, ovarian cancer, or lung cancer.

12. The method of claim **10**, wherein the cancer is triple negative breast cancer.

13. The method of claim **10**, wherein the cancer includes cancer cells that lack receptors for one or more of estrogen, progesterone and epithelial growth factor.

14. The method of claim **10**, wherein administration is by intravenous administration.

15. A method of recruiting and activating neutrophils to destroy a folate receptor alpha (FRA)-expressing cancer cell in a subject, comprising contacting the cancer cell with a conjugate comprising: